Researchers have found evidence that long COVID may damage dopamine releasing neurons in the brain, potentially explaining ...

Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, ...

Why some people experience long-lasting physical and mental effects from covid-19 could be linked to chronic inflammation, according to new research that experts say could help develop new treatments ...

Researchers are studying the curious connection between autoimmune diseases and conditions like POTS and long COVID—in the ...

A new study finds shared biological networks across five very different conditions, offering fresh clues to persistent fatigue and brain fog.

Scientists found up to 20% less dopamine nerve density in long COVID patients, and say the damage tracks closely with ...

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), already a long-neglected condition, has been thrust into the spotlight by COVID-19. ME/CFS is characterized by debilitating fatigue, ...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) reported topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim, an oral investigational drug for Long COVID, showing statistically significant ...

BioVie CEO Cuong Do joined Steve Darling from Proactive to discuss what the company believes is a significant breakthrough in the treatment of long COVID, reporting that its lead drug candidate, ...

Researchers found shared immune, metabolic, mitochondrial, and stress-response networks connecting ME/CFS, long Covid, PTSD, rheumatoid arthritis, and MS.

In Alzheimer’s disease, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its ...